

November 6th 2019, www.corporate.eppendorf.com/en/news-media/newsroom/?layer=/en/press-releases/06122019-eppendorf-with-new-ceo-dual-leadership/
Philipp von Loeper, Chairman of the Supervisory Board of Eppendorf AG, states: “On behalf of the entire Supervisory Board, I want to thank Thomas Bachmann for several successful years of leadership. Eppendorf will continue to execute his comprehensive be Eppendorf 2021 strategy and we appreciate his role in developing this transformative initiative for the company.” The goal of be Eppendorf 2021 is to position the company for continues successful development over the long term by specifically addressing the areas of sales, product innovation and a unique corporate culture. The new leadership will continue the be Eppendorf 2021 strategy and drive the implementation with clear priorities and a highly integrative approach. Source: Eppendorf AG from
More News

Pacira BioSciences Acquires GQ Bio
HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...
Read more …
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …
Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT
medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
Read more …